Ranbaxy introduces two new anti-HIV products as part of World AIDS Day activities

By E. Janene Geiss

Philadelphia, Nov. 30 - Ranbaxy Laboratories Ltd. announced Wednesday that it will introduce two new anti-HIV products, Virolis-E and Virocomb-E, in India on Thursday as part of World AIDS Day activities.

Both products contain three anti-retroviral drugs and offer World Health Organization-recommended first-line Highly Active Anti Retroviral Therapy (HAART) in convenient daily use packs.

The products are designed to improve compliance with HAART, which is presently a challenge faced by both patients and health care providers, officials said in a company news release.

"Ranbaxy is committed to HIV care and this is yet another step in our endeavor to make high quality, affordable and patient-friendly [Anti Retroviral Therapy] available worldwide," said Brian Tempest, chief executive officer and managing director, said in the release.

In most countries outside India, these products will be labeled and sold under the Coviro-E and Avocomb-E brand names respectively, officials said.

Virolis-E is a first of its kind in the world, officials said. It is a compliance pack containing two fixed-dose combination tablets of Lamivudine 150mg and Stavudine 30/40mg and one tablet of Efavirenz 600mg.

Virocomb-E also is a compliance pack and contains two fixed-dose combination tablets of Lamivudine 150mg and Zidovudine 300mg and one tablet of Efavirenz 600mg.

Virolis-E and Virocomb-E are indicated for treatment of HIV-1 infection.

These products will make available Efavirenz-based HAART regimens in convenient daily packs in addition to the convenient Nevirapine-based regimens already made available by Ranbaxy.

Officials said the products are coded with easy-to-read graphics to indicate the time when drugs need to be consumed. The World Health Organization encourages such presentation, as they are expected to enhance compliance to anti-HIV therapy.

Ranbaxy Laboratories Ltd., based in Gurgaon, is India's largest pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.